The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Chemo-immunotherapy (Chemo-ICI) versus chemotherapy (Chemo) alone as a first-line therapy (1L) in extensive-stage small cell lung cancer (ES-SCLC): An individual patient data (IPD)–based synthetic meta-analysis from randomized control trials (RCTs).
 
Arifa Bibi
No Relationships to Disclose
 
Ayesha Aijaz
No Relationships to Disclose
 
Falah Fayaz
No Relationships to Disclose
 
Abhirami Das
No Relationships to Disclose
 
Hassan Abushukair
No Relationships to Disclose
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; BeiGene; Mirati Therapeutics
Speakers' Bureau - Binaytara Foundation - Education Academy
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Biothera (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); InhibRx (Inst); Jacobus Pharmaceutical Company (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Poseida Therapeutics (Inst); SOPHiA Genetics (Inst)
 
Nirmal Choradia
No Relationships to Disclose
 
Raid Aljumaily
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst)
 
Yu Fujiwara
Research Funding - AACR, Johnson & Johnson
Travel, Accommodations, Expenses - Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation
Other Relationship - JMSA Korin Scholarship
 
Alessio Cortellini
Consulting or Advisory Role - Access Infinity; Alira Health; Alpha Sight; Amgen; Ardelis Health; AstraZeneca; Atheneum; Bristol-Myers Squibb; Capvision; Daiichi Sankyo/Astra Zeneca; IQvia; Johnson & Johnson/Janssen; MSD Oncology; Regeneron; Roche; techspert.io; Tegus
Speakers' Bureau - AstraZeneca; Johnson & Johnson/Janssen; MSD Oncology; Roche; Sanofi/Regeneron
Research Funding - IASLC (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche
Other Relationship - BMS; GlaxoSmithKline; MSD Oncology
 
Abdul Rafeh Naqash
Honoraria - NGM Biopharmaceuticals
Consulting or Advisory Role - Astellas Pharma; foundation me; Natera; Regeneron
Speakers' Bureau - natera
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Aravive (Inst); EMD Serono (Inst); IgM Biosciences (Inst); Immunocore (Inst); Inspirna (Inst); Jazz Pharmaceuticals (Inst); Kymera (Inst); Loxo/Lilly (Inst); NiKang Therapeutics (Inst); Phanes Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - American Society for Radiation Oncology; ASCO; Binacea; Conquer Cancer Foundation; Foundation Medicine; IDEOlogy Health; Jazz Pharmaceuticals (Inst); Society for Immunotherapy of Cancer